Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Rachel Ann Freedman, M.D.

Co-Author

This page shows the publications co-authored by Rachel Freedman and Nancy Keating.
Connection Strength

9.882
  1. Individualizing Surveillance Mammography for Older Patients After Treatment for Early-Stage Breast Cancer: Multidisciplinary Expert Panel and International Society of Geriatric Oncology Consensus Statement. JAMA Oncol. 2021 04 01; 7(4):609-615.
    View in: PubMed
    Score: 0.929
  2. Understanding Breast Cancer Knowledge and Barriers to Treatment Adherence: A Qualitative Study Among Breast Cancer Survivors. Biores Open Access. 2017; 6(1):159-168.
    View in: PubMed
    Score: 0.737
  3. Learning from social media: utilizing advanced data extraction techniques to understand barriers to breast cancer treatment. Breast Cancer Res Treat. 2016 07; 158(2):395-405.
    View in: PubMed
    Score: 0.667
  4. Association of Breast Cancer Knowledge With Receipt of Guideline-Recommended Breast Cancer Treatment. J Oncol Pract. 2016 06; 12(6):e613-25.
    View in: PubMed
    Score: 0.662
  5. Higher Stage of Disease Is Associated With Bilateral Mastectomy Among Patients With Breast Cancer: A Population-Based Survey. Clin Breast Cancer. 2016 Apr; 16(2):105-12.
    View in: PubMed
    Score: 0.630
  6. Racial/Ethnic Differences in Patients' Selection of Surgeons and Hospitals for Breast Cancer Surgery. JAMA Oncol. 2015 May; 1(2):222-30.
    View in: PubMed
    Score: 0.616
  7. Racial/ethnic disparities in knowledge about one's breast cancer characteristics. Cancer. 2015 Mar 01; 121(5):724-32.
    View in: PubMed
    Score: 0.605
  8. Patterns of chemotherapy, toxicity, and short-term outcomes for older women receiving adjuvant trastuzumab-based therapy. Breast Cancer Res Treat. 2014 Jun; 145(2):491-501.
    View in: PubMed
    Score: 0.574
  9. Racial/Ethnic differences in receipt of timely adjuvant therapy for older women with breast cancer: are delays influenced by the hospitals where patients obtain surgical care? Health Serv Res. 2013 Oct; 48(5):1669-83.
    View in: PubMed
    Score: 0.538
  10. Use of adjuvant trastuzumab in women with human epidermal growth factor receptor 2 (HER2)-positive breast cancer by race/ethnicity and education within the National Comprehensive Cancer Network. Cancer. 2013 Feb 15; 119(4):839-46.
    View in: PubMed
    Score: 0.515
  11. Receipt of locoregional therapy among young women with breast cancer. Breast Cancer Res Treat. 2012 Oct; 135(3):893-906.
    View in: PubMed
    Score: 0.513
  12. The association of race/ethnicity, insurance status, and socioeconomic factors with breast cancer care. Cancer. 2011 Jan 01; 117(1):180-9.
    View in: PubMed
    Score: 0.449
  13. Trends in racial and age disparities in definitive local therapy of early-stage breast cancer. J Clin Oncol. 2009 Feb 10; 27(5):713-9.
    View in: PubMed
    Score: 0.397
  14. Examining Associations of Racial Residential Segregation With Patient Knowledge of Breast Cancer and Treatment Receipt. Clin Breast Cancer. 2019 06; 19(3):178-187.e3.
    View in: PubMed
    Score: 0.198
  15. Breast cancer-specific survival by age: Worse outcomes for the oldest patients. Cancer. 2018 05 15; 124(10):2184-2191.
    View in: PubMed
    Score: 0.188
  16. Use of Surveillance Mammography Among Older Breast Cancer Survivors by Life Expectancy. J Clin Oncol. 2017 Sep 20; 35(27):3123-3130.
    View in: PubMed
    Score: 0.180
  17. Surveillance Mammography in Older Patients With Breast Cancer-Can We Ever Stop?: A Review. JAMA Oncol. 2017 Mar 01; 3(3):402-409.
    View in: PubMed
    Score: 0.175
  18. Factors Associated with Early Mortality Among Patients with De Novo Metastatic Breast Cancer: A Population-Based Study. Oncologist. 2017 04; 22(4):386-393.
    View in: PubMed
    Score: 0.175
  19. Treatment of early-stage human epidermal growth factor 2-positive cancers among medicare enrollees: age and race strongly associated with non-use of trastuzumab. Breast Cancer Res Treat. 2016 08; 159(1):151-62.
    View in: PubMed
    Score: 0.168
  20. Location Isn't Everything: Proximity, Hospital Characteristics, Choice of Hospital, and Disparities for Breast Cancer Surgery Patients. Health Serv Res. 2016 Aug; 51(4):1561-83.
    View in: PubMed
    Score: 0.162
  21. How Do Payers Respond to Regulatory Actions? The Case of Bevacizumab. J Oncol Pract. 2015 Jul; 11(4):313-8.
    View in: PubMed
    Score: 0.155
  22. Racial differences in outcomes for patients with metastatic breast cancer by disease subtype. Breast Cancer Res Treat. 2015 Jun; 151(3):697-707.
    View in: PubMed
    Score: 0.155
  23. Duration and toxicity of adjuvant trastuzumab in older patients with early-stage breast cancer: a population-based study. J Clin Oncol. 2014 Mar 20; 32(9):927-34.
    View in: PubMed
    Score: 0.142
  24. Cognitive function in older women with breast cancer treated with standard chemotherapy and capecitabine on Cancer and Leukemia Group B 49907. Breast Cancer Res Treat. 2013 Jun; 139(2):607-16.
    View in: PubMed
    Score: 0.135
  25. Trends in co-prescribing of antidepressants and tamoxifen among women with breast cancer, 2004-2010. Breast Cancer Res Treat. 2013 Jan; 137(1):285-96.
    View in: PubMed
    Score: 0.130
  26. Morbidity of local therapy for locally advanced metastatic breast cancer: an analysis of the Surveillance, Epidemiology, and End Results (SEER)-Medicare Registry. Breast Cancer Res Treat. 2018 Jun; 169(2):287-293.
    View in: PubMed
    Score: 0.047
  27. Time trends in incidence rates and survival of newly diagnosed stage IV breast cancer by tumor histology: a population-based analysis. Breast Cancer Res Treat. 2016 06; 157(3):587-96.
    View in: PubMed
    Score: 0.042
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.